2-(4'-iodophenylamino)isophthalic acid | 1005030-11-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4'-iodophenylamino)isophthalic acid
• 英文别名: 2-(4-iodophenylamino)isophtalic acid；2-(4-iodoanilino)benzene-1,3-dicarboxylic acid
• CAS: 1005030-11-4
• 化学式: C₁₄H₁₀INO₄
• 分子量: 383.142
• InChiKey: QTJMEXCOXWQLSI-UHFFFAOYSA-N

物化性质

• 熔点：
  241-243 °C
• 沸点：
  511.5±50.0 °C(predicted)
• 密度：
  1.891±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  86.6
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(4'-iodophenylamino)isophthalic acid 在 PPA 作用下， 反应 2.0h， 以63%的产率得到9,10-dihydro-7-iodo-9-oxoacridine-4-carboxylic acid
  参考文献：
  名称：

  Design, synthesis and preliminary biological evaluation of acridine compounds as potential agents for a combined targeted chemo-radionuclide therapy approach to melanoma

  摘要：

  Various iodo-acridone and acridine carboxamides have been prepared and evaluated as agents for targeted radionuclide and/or chemotherapy for melanoma, due to their structural similarity to benzamides which are known to possess specific affinity for melanin. Three of these carboxamides selected for their in vitro cytotoxic properties were radioiodinated with [I-125] NaI at high specific activity. Biodistribution studies carried out in B16F0 murine melanoma tumour-bearing mice highlighted that acridone 8f and acridine 9d, presented high, long-lasting tumour concentrations together with an in vivo kinetic pro. le favourable to application in targeted radionuclide therapy. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.07.015
• 作为产物：
  描述：

  2-碘异酞酸 、 对碘苯胺 在 N-乙基吗啉 、 copper(l) chloride 作用下， 以 苯 为溶剂， 反应 4.0h， 以62%的产率得到2-(4'-iodophenylamino)isophthalic acid
  参考文献：
  名称：

  Design, synthesis and preliminary biological evaluation of acridine compounds as potential agents for a combined targeted chemo-radionuclide therapy approach to melanoma

  摘要：

  Various iodo-acridone and acridine carboxamides have been prepared and evaluated as agents for targeted radionuclide and/or chemotherapy for melanoma, due to their structural similarity to benzamides which are known to possess specific affinity for melanin. Three of these carboxamides selected for their in vitro cytotoxic properties were radioiodinated with [I-125] NaI at high specific activity. Biodistribution studies carried out in B16F0 murine melanoma tumour-bearing mice highlighted that acridone 8f and acridine 9d, presented high, long-lasting tumour concentrations together with an in vivo kinetic pro. le favourable to application in targeted radionuclide therapy. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.07.015

文献信息

• LABELLED ANALOGUES OF HALOBENZAMIDES AS RADIOPHARMACEUTICALS
  申请人：Madelmont Jean-Claude

  公开号：US20100061928A1

  公开（公告）日：2010-03-11

  The present invention relates to the use of a compound of formula (I): in which R 1 represents a radionuclide, Ar represents an aromatic nucleus, m is an integer varying from 2 to 4, R 2 and R 3 represent, independently of one another, a hydrogen atom, a (C 1 -C 6 )alkyl group, a (C 1 -C 6 )alkenyl group or an aryl group chosen from a phenyl, benzyl, imidazolyl, pyridyl, pyrimidinyl, pyrazinyl, indolyl, indazolyl, furyl and thienyl group, and their addition salts with pharmaceutically acceptable acids, in the preparation of a radiopharmaceutical composition intended for the diagnosis and/or treatment of melanoma.

  本发明涉及使用式（I）化合物：其中R1代表放射性核素，Ar代表芳香环，m为2到4的整数，R2和R3代表独立的氢原子，（C1-C6）烷基，（C1-C6）烯基或苯基，所述苯基选择自苯基，苄基，咪唑基，吡啶基，嘧啶基，吡嗪基，吲哚基，吲唑基，呋喃基和噻吩基，并且它们与药学上可接受的酸的加成盐，用于制备放射性药物组合物，用于诊断和/或治疗黑色素瘤。
• Labelled analogues of halobenzamides as radiopharmaceuticals
  申请人：INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

  公开号：EP2363399A1

  公开（公告）日：2011-09-07

  The present invention relates to the use of a compound of formula (I): in which R1 represents a radionuclide, Ar represents an aromatic nucleus, m is an integer varying from 2 to 4, R2 and R3 represent, independently of one another, a hydrogen atom, a (C1-C6)alkyl group, a (C1-C6)alkenyl group or an aryl group chosen from a phenyl, benzyl, imidazolyl, pyridyl, pyrimidinyl, pyrazinyl, indolyl, indazolyl, furyl and thienyl group, and their addition salts with pharmaceutically acceptable acids, in the preparation of a radiopharmaceutical composition intended for the diagnosis and/or treatment of melanoma.

  本发明涉及式（I）化合物的用途： 其中 R1 代表放射性核素 Ar 代表芳香核 m 是 2 至 4 之间的整数、 R2和R3相互独立地代表氢原子、(C1-C6)烷基、(C1-C6)烯基或选自苯基、苄基、咪唑基、吡啶基、嘧啶基、吡嗪基、吲哚基、吲唑基、呋喃基和噻吩基的芳基，以及它们与药学上可接受的酸的加成盐，用于制备诊断和/或治疗黑色素瘤的放射性药物组合物。
• [EN] LABELLED ANALOGUES OF HALOBENZAMIDES AS RADIOPHARMACEUTICALS<br/>[FR] ANALOGUES MARQUÉS D'HALOBENZAMIDES UTILISÉS COMME PRODUITS RADIOPHARMACEUTIQUES
  申请人：INST NAT SANTE RECH MED

  公开号：WO2008012782A2

  公开（公告）日：2008-01-31

  (EN) The present invention relates to the use of a compound of formula (I): in which R1 represents a radionuclide, Ar represents an aromatic nucleus, m is an integer varying from 2 to 4, R2 and R3 represent, independently of one another, a hydrogen atom, a (C1-C6)alkyl group, a (C1-C6)alkenyl group or an aryl group chosen from a phenyl, benzyl, imidazolyl, pyridyl, pyrimidinyl, pyrazinyl, indolyl, indazolyl, furyl and thienyl group, and their addition salts with pharmaceutically acceptable acids, in the preparation of a radiopharmaceutical composition intended for the diagnosis and/or treatment of melanoma.(FR) La présente invention concerne l'utilisation d'un composé représenté par la formule (I), dans laquelle R1 représente un radionuclide, Ar représente un noyau aromatique, m est un entier variant de 2 à 4, R2 et R3 représentent, indépendamment l'un de l'autre, un atome d'hydrogène, un groupe alkyle en C1-C6, un groupe alcényle en C1-C6 ou un groupe aryle sélectionné parmi le groupe constitué par les groupes phényle, benzyle, imidazolyle, pyridyle, pyrimidinyle, pyrazinyle, indolyle, indazolyle, furyle et thiényle et leurs sels d'addition avec des acides acceptables sur le plan pharmacologique, dans la préparation d'une composition radiopharmaceutique conçue pour diagnostiquer et/ou traiter le mélanome.